Merck & Co., Inc. (MRK) 2024 10-K Earnings Analysis
Merck & Co., Inc.2024 Earnings Analysis
76/100
Merck's FY2024 10-K reveals a company structurally dependent on a single franchise: Keytruda revenue of $29.5B represents 46% of total company sales of $64.2B and 51% of pharmaceutical segment sales of $57.4B. Total revenue grew 7%, net income reached $17.1B at 26.6% net margin, and 76.3% gross margin confirms the patent-protected pricing power. Below the Keytruda concentration sits a fading Covid franchise (Lagevrio down to $964M from $5.7B peak) and a declining diabetes portfolio (Januvia/Janumet down to $2.3B from $4.5B). The Keytruda composition-of-matter patent cliff in 2028 is the overhanging strategic risk — the pipeline must deliver replacements or revenue compresses sharply.
Filing analysis
Merck & Co., Inc. 2024 10-K Analysis
This page reads Merck & Co., Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 76/100, or grade C.
MRK Earnings Quality
The earnings-quality module scores 82/100, with Gross Margin: 76.3%, CF/Net Income: 1.25x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
MRK Economic Moat Analysis
The moat-strength module scores 80/100, with Keytruda Franchise: Dominant, Gardasil HPV Vaccine: Near-monopoly. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
MRK Free Cash Flow vs Net Income
CF/Net Income: 1.25x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
MRK Key Risks from the Annual Report
The risk module scores 62/100, with Keytruda 2028 Cliff: Defining, Diabetes Legacy Decline: Ongoing. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is MRK a High Quality Earnings Stock?
Based on this 2024 filing, MRK passes the first screen for high-quality earnings: the overall grade is C, and the earnings-quality score is 82/100. This is a research screen, not investment advice.
Read the report first
Understand Merck & Co., Inc. first, then decide if it belongs on your watchlist
The MRK score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep MRK with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the MRK report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
76.3% gross margin — typical for patent-protected biologics + oncology therapies. Keytruda (47% of revenue) carries premium pricing globally; Gardasil vaccine franchise adds high-margin volume. Mix is pharma-pure, not diluted by OTC/devices.
OCF of $21.5B against NI of $17.1B = 1.25x — clean conversion, with D&A and working-capital timing producing modest boost. Cash generation is well-aligned with reported earnings.
The 10-K reports Keytruda sales of $29,482M in FY2024, up 18% YoY from $25,011M. This single drug is 47% of total revenue and 51% of pharma segment. Concentration creates both exceptional near-term earnings quality AND the single biggest long-term risk — the 2028 patent cliff.
Lagevrio (molnupiravir) sales of $964M in FY2024 vs $5,684M in FY2022 — the Covid-era therapeutic has declined 83% from peak. The revenue base has already absorbed most of this runoff; FY2024 comparison base is much cleaner than FY2023 was.
Earnings quality scores 82/100. 76.3% gross margin + 1.25x CF/NI confirms the earnings are real high-quality cash. The $29.5B Keytruda stream is the story — exceptional while it lasts, and its 18% growth rate in FY2024 shows the franchise hasn't peaked. The Covid runoff is mostly absorbed; the diabetes legacy is fading but small enough to not move the needle. Quality is high today; the durability question is entirely about post-Keytruda 2028.
Moat Strength
Keytruda is the leading PD-1 inhibitor globally with ~$29.5B revenue across 30+ indications spanning lung, bladder, head-neck, melanoma, cervical, and hematologic cancers. Combination-therapy trials with Lynparza (alliance with AstraZeneca) extend the franchise. Composition-of-matter patent runs to 2028 in US; formulation patents extend longer.
The 10-K reports Gardasil/Gardasil 9 sales of $8,583M in FY2024, slightly below FY2023's $8,886M. The HPV vaccine space is essentially Merck (Gardasil) vs GSK's Cervarix with Merck holding ~85%+ global share. Vaccine moats are durable — manufacturing complexity + regulatory approval create high barriers.
Beyond Keytruda: Winrevair (pulmonary arterial hypertension, 2024 launch), Welireg (kidney cancer), Keytruda subcutaneous (LOE extension strategy), Capvaxive (pneumococcal vaccine, 2024). Several $1B+ potential products but none are Keytruda-scale. The pipeline's ability to offset 2028 cliff remains the central strategic question.
Animal Health sales of $5,877M in FY2024 — Livestock $3,462M + Companion Animal $2,415M. Small relative to human pharma but highly defensive — animal therapeutics have patent protection + relationship-based distribution through veterinarians. Diversification matters when the human pharma concentration is so high.
Moat strength scores 80/100. Keytruda is the dominant franchise asset and Gardasil adds a defensible vaccine moat. The problem is concentration: Keytruda is 47% of revenue, so any challenge to that franchise (biosimilar entry post-2028, competitor PD-1 class improvements, broader pricing pressure) propagates disproportionately. Animal Health provides modest diversification. The pipeline depth question is the central long-term uncertainty.
Capital Allocation
FCF of $18.1B = 28.2% FCF margin on $64.2B revenue. Clean conversion from OCF. Capital returns (dividend + buybacks) are well-covered by FCF; M&A firepower for pipeline-filling deals is substantial.
ROE of 37.0% (NI $17.1B / Equity $46.3B) — solid without extreme engineering. Debt ratio 60% moderate. Merck has managed its capital structure conservatively compared to peers like AbbVie.
Merck has raised dividends for 14+ consecutive years with mid-single-digit growth. Annual payout ~$7.6B is comfortably covered by $18.1B FCF, leaving substantial M&A dry powder.
Merck acquired Prometheus Biosciences ($10.8B, 2023) for immunology, Harpoon Therapeutics (2024), and Imago BioSciences. Focus is pipeline augmentation ahead of the 2028 Keytruda cliff. Execution discipline will determine whether these deals produce successors or become goodwill impairments.
Capital allocation scores 78/100. FCF scale is impressive; dividend discipline + M&A pacing is rational given the 2028 cliff. ROE at 37% is strong without resorting to the extreme buyback-engineered leverage seen in ABBV/HD. The pre-cliff M&A pace is the strategic watchpoint — $10-20B in tuck-ins need to compound into pipeline assets that can materially offset Keytruda decline.
Key Risks
Keytruda composition-of-matter patent expires in the US in 2028. Pembrolizumab biosimilars will enter; historical precedent (Humira) suggests 30-50% first-year revenue erosion on biosimilar launch, accelerating thereafter. This is the single largest earnings risk facing Merck.
The 10-K shows Januvia/Janumet declining from $4,513M in FY2022 to $2,268M in FY2024 — a 50% drop as the DPP-4 class faces IRA Medicare price negotiation + competitive pressure from GLP-1 products (Lilly, Novo). Decline continues.
Januvia was in the first IRA Medicare price negotiation (effective 2026). Keytruda and Gardasil are at risk for future negotiation cycles once they become Medicare-eligible age bracket staples. The erosion path is slow but cumulative.
Several pipeline candidates (Winrevair for PAH, MK-1022 obesity candidates, oncology follow-ons) must deliver to replace Keytruda revenue post-2028. Late-stage trial outcomes are binary — any major Phase 3 failure compounds the cliff problem.
Risk profile scores 62/100 (higher = safer). The 2028 Keytruda cliff is the defining existential question. IRA negotiation and diabetes legacy decline are the slow compounding pressures. Pipeline execution is the binary upside. Merck management knows this and has been pacing M&A appropriately; whether $10-20B in acquired assets can meaningfully replace $29.5B+ of Keytruda by 2030 is the central investment thesis question.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.